The Latest

SEARCH BY KEYWORD
BROWSE BY Category
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

RegenMed Migrates 5,000 Arthrex SOS Cases Onto Circles For The Mackay Clinic

Post
April 1, 2024
Prof. Gordon Mackay is a renowned orthopedic surgeon specializing in ligament and tendon repair, working with elite athletes globally. He is the inventor of the InternalBrace and actively collaborates with orthopedic experts to advance its clinical applications.
Prof. Gordon Mackay is an internationally respected orthopedic surgeon specializing in ligament and tendon repair. He works extensively with high-level athletes in Europe and other parts of the world, and served as the official doctor for the 2014 Ryder Cup at Gleneagles and for the 2014 Commonwealth Games in Glasgow.Prof. Mackay maintains an active practice in the United Kingdom, and is the inventor of the InternalBrace, with the support of Arthrex. Although a busy clinician, he is committed to evidence-based medical research. This includes ongoing collaboration with eighteen leading orthopedic surgeons and consultants around the world to advance the evidence-based clinical applications for the InternalBrace. Prof. Mackay was an early and active user of Arthrex’s Surgical Outcomes System, collecting clinical and long-term outcomes data on over 5,000 patients across six separate SOS modules. When Arthrex decided to sunset SOS in August of 2023, Prof. Mackay chose Circles as his new data collection and analysis platform. RegenMed efficiently migrated onto Circles over 5,000 of his SOS cases, maintaining full data validity conforming to the original SOS modules. Through Circles, Prof. Mackay’s office maintains strong patient engagement for continuing long-term outcomes capture. His office also uses Circles for new cases.
See more
Arrow right

Rediscovering and Re-Imagining Medical Research

Article
March 25, 2024
Medical research has a rich history of breakthrough discoveries made by clinicians and scientists through bold thinking and simple tools. Сurrent medical research is facing challenges such as the limited involvement of busy clinicians, the siloization of research, and the focus on product marketing.
TABLE OF CONTENTS‍THE WAY IT USED TO BEWHAT IT HAS BECOME Return On The Research Dollar The Shrinking Pool Of Innovators The “Siloization” of Medical Research For Whose Benefit? Why Re-Imagine Medical Research?WHAT IT COULD BE AGAIN The Role of Government Democratizing Medical Research The Role of The Busy Clinician The Role of The Medical Scientist The Role of IndustryREAL-WORLD USE CASES Medical Study Formats Independent Provider Groups Academic Medical Centers Medical Societies Product ManufacturersCONTACT USENDNOTESThe Way It Used To BeLong before high speed computers, CRISPR, and artificial intelligence, clinicians and medical scientists achieved major breakthroughs in healthcare through bold thinking and simple tools. They asked the right questions, challenged scientific orthodoxy, looked for answers in the real-world, and let the data lead. John Snow and germ theory, Marie Curie and radiation for neoplasms, Alexander Fleming and penicillin, William Osler and evidence-based medicine – these are among the men and women whose tenacity, scientific method, and commitment yielded discoveries which remain the bedrock of much of modern medicine. It is worth reflecting on their methods. They did not spend months preparing grant proposals. They rarely had access to expensive laboratory equipment, research assistants, budgets, or mentors. They were often ridiculed or even ostracized.But, they had the courage of their convictions – convictions borne of the facts often “hiding in plain sight”. They sought out first principles. They doubted. They replied, “yes, but what if... ?“What It Has BecomeReturn On The Research DollarHundreds of billions of dollars are spent annually on medical research in the U.S. alone. [1] Many ask whether the hoped-for results are being achieved. [2] By some measures of success – articles published, patents granted, dollars raised, grants allocated – one can argue that those billions have been well invested.But high on the list of “key performance indicators” for medical research should be better overall healthcare metrics for broad population groups. Here, there port card is more disappointing. [3] The Shrinking Pool Of InnovatorsMedical students must decide early on whether to practice or “do research”. Some may be fortunate enough to be accepted into research fellowships. Others, employed at academic medical centers, may benefit from limited participation in a research project. The large majority however simply do not have the time or resources for medical research. This is greatly to the detriment of true advancement in healthcare. It is precisely the busy doctors who, each day, must make treatment decisions based on informed observation of real patients. It is they who must wrestle with “standards of care” poorly fitting their patient panels.It is thus the practitioners who are in the best position to collect the most clinically relevant and statistically significant data. It is they who, if only they had the time to analyze those data, could suggest insights of lasting value to medical science.The “Siloization” of Medical ResearchToday’s medical researchers are funneled into ever-narrower areas of study. (This is ironic as the systemic nature of disease becomes more evident.) As a result, there is no shortage of studies, articles, and conference presentations on any topic. Indeed, there is too much information. [4] Unfortunately, much is unhelpful and/or of poor quality. [5]Moreover, even within the same department of an academic medical center, the clinical and research sides rarely interact. Their budgets, motivations, and resources are not only unaligned, they are often at cross purposes. Genuine clinical translation is stifled.PhDs and clinicians should be working arm-in-arm with each other. Both groups should be collaborating with their counterparts in other institutions, and in other fields. Unfortunately, they do so all too infrequently. For Whose Benefit?Medical research in the 21st century is an amalgam of businesses. [6] Clinical research organizations, fund-raising organizations, middle-level managers and consultants, for-profit IRBs, laboratory charges, software systems, and other overhead items all take substantial percentages of the research dollar. Consequently, the remainder which goes into actual research is far less than it could be.Moreover, a large share of research today is funded by well-capitalized medical product manufacturers. Their research objectives and study protocols are understandably focused on marketing approvals for specific products. Achieving statistical significance usually means tightly defined inclusionary/exclusionary criteria in the study sample. This greatly narrows the applicability of the resulting research.Why Re-Imagine Medical Research?The mission statements of all medical research entities are similar – prevention, curing, making a difference for patients, a longer life, a higher quality life, more accessible healthcare. Those laudable goals are, of course, shared by every healthcare professional. They are at the heart of medicine. If these are the right goals, why then does our current approach to medical research deserve careful re-examination? Simply put, because we can do much better.Medical research can be less costly, and more efficient. Involving more healthcare professionals in research, especially those with busy clinical practices, can make a real difference in medical relevance. The advances can have greater impact sooner, and on broader patient populations. There can be greater transparency, and more meaningful collaboration among clinicians, scientists, and industry.What It Could Be AgainThe Role of GovernmentGovernment policies, legislation, and regulations increasingly recognize the importance of more efficient, and more broadly applicable, research. Examples include the 21st Century Cures Act, state and federal “right to try”laws, Expanded Access Programs, NIHs RECOVER (long-Covid) initiative to name a few. Recent FDA guidance also recognizes the important role in regulatory decision-making of real-world evidence. [7]Democratizing Medical ResearchIn the past, ground-breaking medical research was undertaken by clinicians with limited resources, armed only with the intelligence to ask the right questions, and the perseverance to develop causally correlated datasets.This “democratization” of medical research is even more important today. Value-based care, health-equity, and social determinants of health are all pressing healthcare objectives which, by definition, rely on active involvement of as many practitioners as possible.Similarly, they rely on sustained collaboration by those clinicians with medical scientists across institutional and specialty borders. The modern world is highly networked and collaborative. Leading companies in non-healthcare industries regularly develop and analyze large amounts of information in an efficient manner. They equally efficiently convert those data into useful products and processes. Conversely, medicine often utilizes old approaches, with impactful clinical translation delayed because of self-imposed constraints. It need not be so.The Role of The Busy ClinicianThe goal of medical research is clinical usefulness – more accurate diagnoses, superior and more predictable outcomes from a particular intervention, better healthcare for broader patient populations, higher levels of evidence for standards of care.Therefore, clinicians and their patients should not be distant, potential beneficiaries of medical research. Rather, they should be active participants. Clinicians will often establish the most promising hypotheses; they have access to the richest and most validated datasets; they are the first to observe correlated outcomes; they are the most impartial. The Role of The Medical ScientistToday’s medical scientist has access to enormous amounts of literature, laboratory resources, analytical tools, and other resources often unavailable to the busy physician. She is at her best when she uses these assets not to study something “small”, but rather something with a large impact. This she does by questioning the literature, by looking for first principles, by reviewing the work of thought leaders in adjacent fields – even outside of medicine. Equally important for meaningful medical research, she seeks out and works closely with co-investigators, including practicing physicians. The Role of IndustryIndustry has always played a major role in medical research. That research will largely be dedicated to receiving product marketing approval. But approved products also require ongoing post-market surveillance and support for new indications. This do calls for efficient approaches to statistically and clinically significant research.Medical research programs are important not only for large, well-capitalized companies. They are also a strategic imperative for OTC products, compounded pharmaceuticals, nutraceuticals and other “health and wellness” offerings. These research programs go well beyond regulatory requirements; they are essential to competitive differentiation.Leading product manufacturers have long recognized the value of working closely and ethically with external practitioners and scientists. Investigator-initiated studies and similar programs often represent the foundation of INDs, IDE’s510-Ks, ongoing product improvement and intellectual property development. [8]Real-World Use CasesThe democratization of quality medical research is well underway. Following are some use cases.Medical Study FormatsRandomized clinical trials (“RCT’s”) remain the gold standard for evidence-based standards of care. However, due to their cost and duration, the vast majority of such RCT’s are designed and paid for by product manufacturers. The purpose and design of such trials reduces their applicability to most real-world patient populations. Consequently, many if not most “standards of care” in modern medicine are not supported by RCTs or other quality evidence. This has led to a proliferation of “registries” [9] and study design types – pragmatic, quality improvement, observational, and other – which if properly designed and executed can represent clinically and statistically significant datasets. [10] Independent Provider GroupsASCs, physician owned hospitals, and other independent medical practice groups are well positioned for impactful medical research.They represent large case volumes, diverse patient populations, centralized systems, existing collaboration processes, and, often, a research director.Moreover, as hematology analyzers, cell counters, imaging devices and other laboratory equipment become more accessible, independent practice groups can perform sophisticated scientific assays which were previously out of reach for them.As a result, many independent provider groups are capitalizing on the scientific, clinical, and financial value of “real-world evidence” research programs.Academic Medical CentersIn principle, teaching hospitals should be “hotbeds” of impactful medical research. That impact is often thwarted however by complex internal processes, unclear IP attribution rights, weak collaboration between the “clinical” and “science” departments, high study costs, and misaligned budgetary incentives.Small pilot projects – focusing on value-based care within a single department for example – can provide the template for larger initiatives.Also, a multi-center study not only allows investigators to participate with colleagues across institutional and national borders, it often streamlines the IRB process.Medical SocietiesMedical societies can represent the vanguard of medical research in their respective fields. Indeed, many have played this role historically. There are challenges, however: part time and short-term participation of society board members, a focus on annual conferences, and the lack of a research culture delivering demonstrable clinical value to society members. Those societies paying attention to the clinical decision-making challenges of their members will thrive. Such societies also effectively intermediate industry research support and the involvement of thought-leader members in the design and execution of impactful study protocols. Product ManufacturersFor manufacturers, research and clinical studies are at the heart of product development, regulatory approvals, and HCP communications. They are also increasingly important for patient education and compliance.By exploiting the full potential of investigator-initiated trial programs, product registries, and post-market surveillance, manufacturers can realize several strategic benefits. These include deeper relationships with key opinion leaders, sustained engagement with clinical customers, more and faster product development insights, and more efficient regulatory submission processes.Contact UsTo find out more, please contact us.Endnotes1 https://www.researchamerica.org/wp-content/uploads/2022/09/ResearchAmerica-Investment-Report.Final_.January-2022-1.pdf. 2 Is The Pace of Biomedical innovations Slowing? Casedeval. Why Medical Innovation Is Slow To Reach Patients.3 Mirror, Mirror 2021 Reflecting Poorly, Commonwealth Fund. 4 Fixing Data Overload In Healthcare, Harvard Business Review.5 Methodology Over Metrics:Current Scientific Standards Are A Disservice To Patients And Society.6 The Business of Clinical Trials Is Booming. Private Equity HasTaken Notice. The Business of Clinical Trials: Who Pays? Who Profits?7 See for example FDA, Real World Evidence, FDA, Post-Market Surveillance Programs; The 21st Century Cures Act; NIH Grants Program For Real-World Studies; Expect To See More RWE-Based Regulatory Decisions, Robert Califf, FDA Commissioner; Use Of Real-World Evidence In Regulatory DecisionMaking, EuropeanMedicines Agency.8 See Investigator Initiated Trials. 9 See Registries for Evaluating Patient Outcomes: A User's Guide: 4th Edition, Agency for Healthcare and Quality and Research, U.S. Department of Health and Human Services.10 See Pragmatic Trials, NEJM, Ford and Norrie, Quality Improvement Projects and Clinical Research Studies, Faiman, and Quality Improvement In Practice, Backman.Copyright © 2024 Regenerative Medicine LLC
See more
Arrow right

The Power Of Bilateral Surveys

Post
March 13, 2024
Clinicians often treat patients with bilateral indications, such as osteoarthritis in both knees, which makes capturing data on bilateral diagnoses, treatments, and outcomes challenging. Circles with bilateral surveys address these challenges.
Musculoskeletal and other clinicians often treat patients presenting with bilateral indications – osteoarthritis in both knees for example. Relatedly, a patient treated for OA in only one shoulder is likely to require treatment for the other soon. However, there are typically material differences in the clinical assessments, interventions and patient reported outcomes for each anatomical area. This poses a challenge in the efficient capture of data related to bilateral diagnoses, treatments, and outcome follow-up. These challenges are now accommodated through a major new Circles capability – Bilateral Surveys. Whether on a mobile or desktop device, practitioners or their staff can now easily capture in a single survey diverse clinical datapoints for each bilateral anatomical area. Similarly, patients can report outcomes on standardized or custom assessments for both areas in a single survey. This amplifies the statistical and clinical significance of aggregated datasets, since the clinical and outcomes data associated with each anatomical area are reported separately. It also allows a clinician or researcher to utilize one anatomical area as a control in the context of a study. Contact us to find out more about Bilateral Surveys and their use cases.
See more
Arrow right

Cost Reduction in Healthcare

Post
March 11, 2024
Reduction of operating expenses is a strategic imperative in all businesses. This is nowhere more true than in healthcare. Whether a large hospital system, an independent provider group, a product manufacturer, or a payer, continuing to drive financial efficiency is critical to survival.
Reduction of operating expenses is a strategic imperative in all businesses. This is nowhere more true than in healthcare. Whether a large hospital system, an independent provider group, a product manufacturer, or a payer, continuing to drive financial efficiency is critical to survival. Reduced valuations, inability to grow, layoffs and even bankruptcies of every category of healthcare company are everyday occurrences.Data collection and analysis represent a major cost center for each of these categories. It is increasingly difficult to justify expensive EMR systems, research platforms, internal servers — and the personnel and vendor costs associated with them. “Data” was supposed to constitute a positive return on investment. In fact, not only is that ROI proving to be negative, it is so negative as to threaten financial stability of the entity. Healthcare data are undoubtedly important. Indeed, the right datasets are more important than ever. Validated fit-for-purpose datasets lead to better and more predictable clinical outcomes, to product development, to value-based care, to health equity. As such they can represent a profit center. Moreover, those datasets can be developed for a fraction of the price currently paid by healthcare companies. For the type of datasets which make a difference, modern technology enables superior substantial cost reduction and superior user experience for clinicians, support staff, researchers, and patients.Contact us to learn more.
See more
Arrow right

Healthcare IP Development Through Circles

Post
March 7, 2024
Many provider groups and product manufacturers recognize the inherent value of validated, well-structured datasets generated in the busy clinical setting. Meanwhile, independent practice groups are now in an equally strong position to develop and capture IP value through real-world evidence programs
Type image caption here (optional)Many provider groups and product manufacturers recognize the inherent value of validated, well-structured datasets generated in the busy clinical setting. (The FDA, payers and others refer to such datasets as real-world evidence.) A major category of thoughtfully-designed and executed real-world evidence programs is intellectual property – inventions, patents, trade secrets, and copyrights. Most large hospital systems now have “innovation centers”, “tech transfer departments” and similar units designed to generate license revenues. They generally fail, however, to tap into RWE, the richest source of such IP. Moreover, their revenue shares for clinician inventors, and complex IP processes, may often stifle rather than incentivize marketable inventions. Meanwhile, independent practice groups are now in an equally strong position to develop and capture IP value through real-world evidence programs. They can do so on their own, accumulating and curating fit-for-purpose RWE until its clinical significance warrants licensing and monetization. Alternatively, they can partner with product manufacturers in establishing an RWE program designed to maximize specific IP objectives from the beginning.In all cases, Circles represent a robust yet low-cost platform, with excellent user experience, for designing and implementing RWE programs leading to IP value. Contact us to learn more.
See more
Arrow right
Nothing was found. Please use a single word for precise results.
Stay Informed.
Subscribe for our newsletter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.